Emerging treatments for primary sclerosing cholangitis
Authors:
- 22 February 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 11 (5) , 451-459
Abstract
Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.Keywords
This publication has 90 references indexed in Scilit:
- Alcohol consumption in patients with primary sclerosing cholangitisWorld Journal of Gastroenterology, 2012
- Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitisDigestive and Liver Disease, 2011
- Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosisJournal of Experimental & Clinical Cancer Research, 2010
- Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cellsHepatology, 2010
- Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cellsCancer Letters, 2010
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #Hepatology, 2009
- Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 −/− mice†‡§Hepatology, 2009
- International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitisJournal of Hepatology, 1999
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Ursodeoxycholic acid for primary sclerosing cholangitisJournal of Hepatology, 1990